Revised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)
The international rulebook for pancreatic cysts: which features mean a cyst should be removed straight away (high-risk stigmata), which mean it needs a closer look with endoscopic ultrasound (worrisome features), and how often smaller cysts should be scanned.
Overview
Revision of the 2012 Fukuoka consensus from the International Association of Pancreatology for intraductal papillary mucinous neoplasms and mucinous cystic neoplasms. High-risk stigmata that indicate resection are obstructive jaundice from a cyst in the head, an enhancing mural nodule of 5 mm or more and a main pancreatic duct of 10 mm or more. Worrisome features that indicate endoscopic ultrasound include cyst size of 3 cm or more, enhancing mural nodule under 5 mm, thickened enhancing cyst walls, main duct 5 to 9 mm, abrupt change in duct calibre with distal atrophy, lymphadenopathy, raised CA19-9 and cyst growth of 5 mm or more in two years.
Surveillance intervals for cysts without these features are set by cyst size, and the revision addresses surgery for main-duct IPMN, extent of resection and follow-up after resection.
- High-risk stigmata for resection: obstructive jaundice, enhancing mural nodule 5 mm or more, main duct 10 mm or more.
- Worrisome features for endoscopic ultrasound: cyst 3 cm or more, small nodule, thickened wall, main duct 5 to 9 mm, raised CA19-9, growth 5 mm in two years, among others.
- Size-based surveillance intervals for cysts without worrisome features.
Most radiology reports and surgical decisions on pancreatic cysts still follow the Fukuoka criteria or their 2024 Kyoto revision.
- Expert consensus resting on retrospective series; no randomised trial of surveillance strategies exists.
- The criteria are sensitive but not specific, so many resected cysts turn out to be low grade.
Similar pages
not linked directly; found by shared links- Key paperEuropean evidence-based guidelines on pancreatic cystic neoplasms (2018)
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- Key paperInternational evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- IdeaGlucose monitor data as an early pancreatic cancer signal
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- IdeaStop watching stable low-risk pancreatic cysts after five years
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- PersonDiane M. Simeone
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- IdeaNew diabetes after 50 plus weight loss triggers a pancreatic cancer check
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- IdeaAI that spots pancreatic cancer on scans taken a year before diagnosis
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- PersonRichard Schulick
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.